{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:47:00Z","timestamp":1780044420503,"version":"3.53.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ygyno.2021.05.015","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T02:40:01Z","timestamp":1621910401000},"page":"345-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis"],"prefix":"10.1016","volume":"162","author":[{"given":"Beryl L.","family":"Manning-Geist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ygyno.2021.05.015_bb0005","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"issue":"38","key":"10.1016\/j.ygyno.2021.05.015_bb0010","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGTO-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.05.015_bb0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2021.05.015_bb0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.015_bb0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2010.01.046","article-title":"Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series","volume":"117","author":"Shih","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.015_bb0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2006.08.037","article-title":"Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome","volume":"104","author":"Karam","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.05.015_bb0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ygyno.2017.07.008","article-title":"Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: a multicentre MITO retrospective study","volume":"147","author":"Falcone","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.05.015_bb0040","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","article-title":"Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation","volume":"20","author":"Fotopoulou","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.05.015_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12957-017-1200-x","article-title":"Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Mullerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402)","volume":"15","author":"Hirakawa","year":"2017","journal-title":"World J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.05.015_bb0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.7314\/APJCP.2016.17.4.1909","article-title":"Tertiary cytoreduction for recurrent epithelial ovarian cancer: a multicenter study in Turkey","volume":"17","author":"Arvas","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.ygyno.2021.05.015_bb0055","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/s10434-014-4141-4","article-title":"Development and assessment of memorial sloan kettering cancer center\u2019s surgical secondary events grading system","volume":"22","author":"Strong","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2021.05.015_bb0060","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Dubois","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2021.05.015_bb0065","article-title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2","volume":"38","author":"Zang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.015_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.05.015_bb0075","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2021.05.015_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/mdx443","article-title":"Real-world evidence in the treatment of ovarian cancer","volume":"28","author":"Eisenhauer","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.05.015_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:54:13Z","timestamp":1758772453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821004212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0090825821004212"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}